P/E ratio for Exelixis (EXEL)
P/E ratio as of May 2024 (TTM): 74.5
According to Exelixis's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 74.5499. At the end of 2022 the company had a P/E ratio of 28.1.
P/E ratio history for Exelixis from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 28.1 | 13.92% |
| 2021 | 24.7 | -54.46% |
| 2020 | 54.2 | 226.32% |
| 2019 | 16.6 | 94.37% |
| 2018 | 8.55 | -85.09% |
| 2017 | 57.4 | -226.95% |
| 2016 | -45.2 | 540.88% |
| 2015 | -7.05 | 580.52% |
| 2014 | -1.04 | -77.69% |
| 2013 | -4.64 | -6.51% |
| 2012 | -4.97 | -158.69% |
| 2011 | 8.46 | -187.63% |
| 2010 | -9.66 | 65.13% |
| 2009 | -5.85 | 78.27% |
| 2008 | -3.28 | -66.92% |
| 2007 | -9.92 | 28.95% |
| 2006 | -7.69 | -11.81% |
| 2005 | -8.72 | 73.53% |
| 2004 | -5.03 | 3.38% |
| 2003 | -4.86 | -7.01% |
| 2002 | -5.23 | -51.55% |
| 2001 | -10.8 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.8 | -85.46% | 🇺🇸 USA |
 Pfizer PFE | 15.5 | -79.22% | 🇺🇸 USA |
 Amgen AMGN | 22.5 | -69.76% | 🇺🇸 USA |
 Sanofi SNY | 15.4 | -79.33% | 🇫🇷 France |
 Merck MRK | 72.3 | -3.00% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 11.2 | -84.95% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 13.1 | -82.49% | 🇬🇧 UK |
 Curis CRIS | -1.30 | -101.74% | 🇺🇸 USA |
 AVEO Oncology
AVEO | -17.9 | -123.95% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.